WO2023201278 - PROGRAMMABLE DELIVERY OF RNA-GUIDED CRISPR-CAS PROTEINS TO SUBCELLULAR ORGANELLES
National phase entry is expected:
Publication Number
WO/2023/201278
Publication Date
19.10.2023
International Application No.
PCT/US2023/065695
International Filing Date
14.04.2023
Title **
[English]
PROGRAMMABLE DELIVERY OF RNA-GUIDED CRISPR-CAS PROTEINS TO SUBCELLULAR ORGANELLES
[French]
ADMINISTRATION PROGRAMMABLE DE PROTÉINES CRISPR-CAS GUIDÉES PAR ARN À DES ORGANITES SUBCELLULAIRES
Applicants **
MONTANA STATE UNIVERSITY
Inventors
WIEDENHEFT, Blake, A.
NEMUDRAIA, Anna, A.
NEMUDRYI, Artem, A.
Priority Data
63/329,952
12.04.2022
US
63/450,339
06.03.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2150 | |
| EPO | Filing, Examination, Granting | 11426 | |
| Japan | Filing, Examination, Granting | 2161 | |
| South Korea | Filing, Examination, Granting | 2025 | |
| USA | Filing, Examination, Granting | 4310 |
Total:
22,072
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Engineered CRISPR proteins may be generated for localized anchoring to targeted cellular locations. Engineered CRISPR proteins may be generated by a lipidation motif with a CRISPR protein. The lipidation motif may be post-translationally modified to anchor the lipidation motifs and the fused CRISPR protein to a targeted cellular location, such as membranes of organelles associated with viral infections or other ailments. To account for possible additional amino acids that might affect the efficiency of post-translational modifications, linkers derived from C-terminal ends OAS1 (p46 isoform) and ZAP-L proteins may be used. Different fusion designs and/or different lipidation motifs may be used to target CRISPR proteins to specific and respective cellular locations. Targeted cellular- localization of engineered CRISPR proteins may enable targeted therapies involving the engineered CRISPR proteins.[French]
Des protéines CRISPR modifiées peuvent être générées pour un ancrage localisé à des emplacements cellulaires ciblés. Des protéines CRISPR modifiées peuvent être générées par un motif de lipidation avec une protéine CRISPR. Le motif de lipidation peut être modifié post-traductionnellement pour ancrer les motifs de lipidation et la protéine CRISPR fusionnée à un emplacement cellulaire ciblé, tel que des membranes d'organites associés à des infections virales ou à d'autres affections. Pour tenir compte d'éventuels acides aminés supplémentaires qui pourraient affecter l'efficacité de modifications post-traductionnelles, des lieurs dérivés des extrémités C-terminales OAS1 (isoforme p46) et des protéines ZAP-L peuvent être utilisés. Différentes conceptions de fusion et/ou différents motifs de lipidation peuvent être utilisés pour cibler des protéines CRISPR à des emplacements cellulaires spécifiques et respectifs. La localisation cellulaire ciblée de protéines CRISPR modifiées peut permettre des thérapies ciblées impliquant les protéines CRISPR modifiées.